Update on belimumab for the management of systemic lupus erythematosus

Expert Opinion on Biological Therapy

Volumn 14, Issue 11, 2014, Pages 1701-1708

  Lutalo, Pamela M K ^a   D'Cruz, David P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

B cell depletion; B lymphocyte stimulator; Belimumab; Systemic lupus erythematosus

Indexed keywords

BELIMUMAB; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; PLACEBO; B CELL ACTIVATING FACTOR; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY;

AFRICAN; ARTICLE; BASAL CELL CARCINOMA; BREAST CANCER; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COLON CANCER; CORTICOSTEROID THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; HEALTH CARE QUALITY; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFUSION RELATED REACTION; KIDNEY CARCINOMA; LONGITUDINAL STUDY; LUNG CANCER; LUPUS ERYTHEMATOSUS NEPHRITIS; MELANOMA; MULTICENTER STUDY (TOPIC); NORTH AMERICA; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; MORTALITY; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B-CELL ACTIVATING FACTOR; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84911166149     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.959924     Document Type: Article

References (20)

1. Choi J, Kim ST, Craft J. The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol 2012;24(6):651-7
2. D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007;369(9561):587-96
3. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008;358(9):929-39
4. Sestak AL, Furnrohr BG, Harley JB, et al. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis 2011;70(Suppl 1):i37-43
5. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus 2009;18(13):1136-43
6. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW. Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 2007;56(4):1251-62
7. Symmons DP. Frequency of lupus in people of African origin. Lupus 1995;4(3):176-8
8. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs 2010;70(5):529-40
9. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377(9767):721-31
10. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63(12):3918-30
11. Luijten KM, Tekstra J, Bijlsma JW, Bijl M. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012;11(5):326-9
12. Data on file. Study 117295. 2012.Available from: http://www.gsk-clinicalstudyregister.com
13. Ginzler EM, Wallace DJ, Merrill JT, et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 2014;41(2):300-9
14. Collins CE, Dall'Era MO, McGuire A, et al. 12-month outcomes associated with belimumab in patients with systemic lupus erythematosus in clinical practice settings: the observe study [abstract]. Arthritis Rheum 2013;65(Suppl):1740
15. Strand V, Levy RA, Cervera R, et al. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis 2014;73(5):838-44
16. Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64(10):3364-73
17. Bernatsky S, Boivin JF, Joseph L, et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005;52(5):1481-90
18. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54(8):2550-7
19. Fredericks C, Kvam K, Bear J, et al. A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus 2014. [Epub ahead of print]
20. Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 2013;22(1):63-72